A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)

This study evaluates whether guselkumab (a medication that blocks inflammation) can help control Crohn's disease — a condition causing chronic inflammation in the digestive tract — in Chinese patients who have not responded well to a previous biologic drug called ustekinumab. **You may be eligible if...** - You have a confirmed diagnosis of active Crohn's disease - Your disease is currently active, with significant abdominal pain or frequent loose stools - You previously received ustekinumab but did not have an adequate response **You may NOT be eligible if...** - Your Crohn's disease is currently in remission - You have not previously been treated with ustekinumab as per the study protocol - You have certain infections or other conditions that exclude participation Talk to your doctor to see if this trial is right for you.